Cai Xin

CSPC Pharma weighs up diet drug for bigger bottom line

CSPC Pharma weighs up diet drug for bigger bottom line

After three years of sluggish growth, the company has delivered higher quarterly earnings from sales of existing drugs and is exploring new avenues in the weight-loss business  Key Takeaways: CSPC…
1093.HK

Recent Articles

RELATED ARTICLES

  1. Liu Yongjun’s experience in the commercialization of innovative drugs and his connections with multinational pharmaceutical companies are urgently needed for CSPC Pharmaceutical’s ongoing transformation.
    CSPC Pharma taps R&D superstar in quest for new breakout drugs
    1093.HK
  2. Akeso marks profit milestone with swift rights issue
    9926.HK
  3. Novel drugs lift Sino Biopharm earnings, easing price-cap pain
    1177.HK
  4. Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
    1952.HK
  5. InSilico seeks IPO boost to get AI drugs over the line
  6. Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
    1672.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva